

# Anticoagulation Comparison Chart

## A Quick Guide for Prescribers

### Key

- ☑ Indicated
- ☒ Not Indicated

### Acute medical illness

Conditions such as pneumonia, stroke, heart failure, infection, or inflammatory disease

### CAD

Coronary artery disease

### MAJOR CARDIOVASCULAR (CV) EVENTS

CV death, heart attack, and stroke

### PAD

Peripheral artery disease

	Jantoven® Warfarin <sup>2</sup>	Eliquis. (apixaban) tablets Apixaban	Xarelto rivaroxaban Rivaroxaban	Pradaxa dabigatran etexilate Dabigatran	Savaysa (edoxaban) tablets Edoxaban
GENERIC	Yes	No	No	Yes	No
<b>INDICATIONS APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA)</b>					
<b>Stroke Prevention in Atrial Fibrillation (AF)</b>					
AF without mechanical valves or mitral valve stenosis	☑	☑	☑	☑	☑
AF with mechanical valves or mitral valve stenosis	☑	☒	☒	☒	☒
<b>Venous Thromboembolism (VTE)</b>					
Treatment of VTE	☑	☑	☑	☑	☑
Secondary prevention in patients already treated for VTE	☒	☑	☑	☑	☒
Prophylaxis after hip replacement surgery	☒	☑	☑	☑	☒
Prophylaxis after knee replacement surgery	☒	☑	☑	☒	☒
Prophylaxis in the hospital and after discharge in adults with acute medical illness	☒	☒	☑	☒	☒
Prophylaxis of major cardiovascular events in patients with CAD and/or PAD – and in combination with aspirin	☒	☒	☑	☒	☒
Drug image and available dosages	 Colors and shapes vary by dose	 2.5 mg 5 mg	 2.5 mg 15 mg 10 mg 20 mg	 75 mg 110 mg 150 mg	 15 mg 30 mg 60 mg
Onset	Days	Hours	Hours	Hours	Hours
Kidney Function	No	Yes	Yes	Yes	Yes
Food effects	Yes Vitamin K Interactions	No	Yes Must take 15-mg and 20-mg doses with food	No	No
Drug Interactions	Many	Few	Few	Few	Few
Routine drug monitoring	Yes	Not Needed	Complete blood count and kidney/liver function tests recommended annually (more frequently in some patients)		
Reversal Agents If FDA-approved agents aren't available, 4-factor prothrombin complex concentrate (4F-PCC; brand name KCentra®) is an alternative for all agents.	Yes 4F-PCC Vitamin K, fresh frozen plasma	No* *Andexxa® (andexanet alfa) was withdrawn from the U.S. market in 2025.	No* *Andexxa® (andexanet alfa) was withdrawn from the U.S. market in 2025.	Yes* Praxbind® (idarucizumab)	No No FDA-approved reversal agents currently

For more information, please visit [thrombosis.org](http://thrombosis.org)